Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study
David S. Reeves, RICHARD W. LACEY, R V Mummery, Mahendra Kumar M, A. J. Bint, S.W.B. Newsom
Abstract
David S. Reeves, RICHARD W. LACEY, R V Mummery, Mahendra Kumar M, A. J. Bint, S.W.B. Newsom
Abstract
The efficacy, tolerability and side effects of a 3-day treatment for acute urinary infection in general practice with norfloxacin (400 mg 12 hourly) or nalidixic acid/citrate (1 sachet 8 hourly) were compared in a randomized study. Patient groups had similar demography, symptomatology and initial infecting bacteria. Of the evaluable 55 patients in each treatment group with initial bacteriuria, 53 (96%) had no bacteriuria at immediate follow-up after treatment with norfloxacin and 45 (82%) with nalidixic acid/citrate. The corresponding rates at late follow-up were 40/45 (89%) and 29/43 (67%) (P less than 0.05). Among the bacteriuric patients a significantly greater proportion were recorded as having cured and improved symptoms. The tolerability of norfloxacin seemed to be better than that of nalidixic acid/citrate.
OpenAlex reports 42 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The efficacy, tolerability and side effects of a 3-day treatment for acute urinary infection in general practice with norfloxacin (400 mg 12 hourly) or nalidixic acid/citrate (1 sachet 8 hourly) were compared in a randomized study. Patient groups had similar demography, symptomatology and initial infecting bacteria. Of the evaluable 55 patients in each treatment group with initial bacteriuria, 53 (96%) had no bacteriuria at immediate follow-up after treatment with norfloxacin and 45 (82%) with nalidixic acid/citrate. The corresponding rates at late follow-up were 40/45 (89%) and 29/43 (67%) (P less than 0.05). Among the bacteriuric patients a significantly greater proportion were recorded as having cured and improved symptoms. The tolerability of norfloxacin seemed to be better than that of nalidixic acid/citrate.
Key concepts: Norfloxacin, Nalidixic acid, Library science, Medicine, History, Computer science, Antibiotics, Microbiology